This document defines the indicator "Percentage of infants born to HIV-positive women who had a virologic HIV test done within 12 months of birth". It provides details on the numerator, denominator, and disaggregation categories for this indicator, which measures how many exposed infants receive early testing to determine their HIV status. Early diagnosis is critical to ensure untreated infants receive necessary treatment. The document also describes how to calculate and interpret this indicator, and what types of PEPFAR support can be counted.
Infographic: A Day in the Life of Infection PreventionistsQ-Centrix
A look at a day in the life of a hospital Infection Preventionist (IP). As IPs' roles expand, their hectic day includes making rounds on the hospital floor, enforcing procedures, educating staff, providing proactive counsel...and sometimes spending 5+ hours/day collecting and reporting data to federal health agencies.
.
Zimbabwe: Results-Based Financing Improves Coverage, Quality and Financial Pr...RBFHealth
A presentation by Dr. Gwinji, Permanent Secretary, Ministry of Health, Zimbabwe and Dr. Tafadzwa Goverwa- Sibanda, delivered during "Transforming Health Systems Through Results-Based Financing," an event held during the Third Global Symposium on Health Systems Research in Cape Town on September 30, 2014. This event was hosted by the Health Results Innovation Trust Fund at The World Bank, in partnership with the PBF Community of Practice in Africa.
Infographic: A Day in the Life of Infection PreventionistsQ-Centrix
A look at a day in the life of a hospital Infection Preventionist (IP). As IPs' roles expand, their hectic day includes making rounds on the hospital floor, enforcing procedures, educating staff, providing proactive counsel...and sometimes spending 5+ hours/day collecting and reporting data to federal health agencies.
.
Zimbabwe: Results-Based Financing Improves Coverage, Quality and Financial Pr...RBFHealth
A presentation by Dr. Gwinji, Permanent Secretary, Ministry of Health, Zimbabwe and Dr. Tafadzwa Goverwa- Sibanda, delivered during "Transforming Health Systems Through Results-Based Financing," an event held during the Third Global Symposium on Health Systems Research in Cape Town on September 30, 2014. This event was hosted by the Health Results Innovation Trust Fund at The World Bank, in partnership with the PBF Community of Practice in Africa.
OpenNotes: Transparent Clinicians' Notes for Health & IllnessOpenNotes
Sharing clinicians’ notes with patients is a simple idea for health. This presentation can be used to introduce your institution to the benefits of open notes and how to adopt this practice with your patients. It guides you through the OpenNotes study, which sparked a movement towards more transparent notes across the nation.
White Paper - Infection Preventionists: Healthcare’s Guardians at the Gate Ne...Q-Centrix
This white paper examines a key player at the front lines of hospitals’ never-ending battles against HAIs –Infection Preventionists (IPs). It briefly explains their varied roles, responsibilities and new challenges, the difficulty in recruiting these highly sought-after experts, and why and how hospitals should be doing more to help overworked and understaffed IPs be successful. Lastly, it covers new technologies and IP support services that can be integrated into hospitals’ infection control practices.
Same-Visit Contraception: Implementation Strategies from the FieldJSI
According to the CDC and OPA, clients should have access to their contraceptive method of choice without unnecessary delays. Same-visit provision of contraception means providing immediate access to contraceptive methods using Quick Start. As long as a clinician can be reasonably certain a client is not pregnant, there is not medical reason to require clients to return for a follow-up visit or to initiate methods during menses. Clients face many barriers (work, child care, secure transportation) when asked to return for a second visit in order to initiate contraception and up to 50% of clients will not return for a follow up appointment.
Title X grantees and service sites across the country to identify successful strategies for implementing same-visit contraception including: 1. Stock devices and make supplies readily available, 2. Adjust systems for efficient and sustainable service delivery, 3. Engage, train, and support all staff.
To support implementation to Title X service sites, the FPNTC provides a Same-Visit Contraception Guide which includes: video case studies, slides and a discussion guide, interactive tools including checklists, calculators and printable sheets that can be posted at the office.
Kathy Talkington and Joe Swedberg - Antibiotic Stewardship – Recent Activitie...John Blue
Antibiotic Stewardship – Recent Activities in Human Medicine and Animal Agriculture - Kathy Talkington, Project Director, Antimicrobial Resistance, The Pew Charitable Trusts; Joe Swedberg, Chairman of the Board, Farm Foundation, from the 2018 NIAA Antibiotic Symposium: New Science & Technology Tools for Antibiotic Stewardship, November 13-15, 2018, Overland Park, KS, USA.
More presentations at https://www.youtube.com/playlist?list=PL8ZKJKD9cmEffjOrjbBvQZeN2_SZB_Skc
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
In pursuit of the 90–90–90 goals, emphasis has been placed on accelerating centralized laboratory HIV viral load testing of a population that is largely rural and decentralized. Successful
outcome requires effective specimen transport, laboratory testing, and results delivery. This paper focuses on the methods currently employed for results delivery. New innovations in this area are
yielding mixed results; we analyze different approaches and estimate the impact of each on achieving the third ‘90.’
With patient responsibility becoming an increasing part of clinics AR, you need to make sure you have an effective strategy in place. Learn how to maximize your collections without negatively impacting your relationships with your patients.
The Clinical Trials Portal supports improved cancer clinical trial activity data capture, monitoring and reporting across NSW. Find out more about cancer clinical trials in NSW.
Monitoring quality of care: making the most of dataNuffield Trust
Chris Sherlaw-Johnson, Senior Research Analyst at the Nuffield Trust, introduced the Monitoring quality of care conference and gives an overview of some of the approaches that we've been using at the Trust to identify where care quality has been improving, especially for frail and older people.
Patient Registries: A New Pillar of Modern CareQ-Centrix
www.q-centrix.com
A vital resource for patient data are registries. This white paper examines the rise of patient registries, how hospitals are taking advantage of the data, the challenges hospitals face in submitting quality information, and the benefits of real-time registry reporting.
AMCCBS Virtual2021 Conference Takeaways Part 2Carevive
Check out Debra Wujcik's takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms.
OpenNotes: Transparent Clinicians' Notes for Health & IllnessOpenNotes
Sharing clinicians’ notes with patients is a simple idea for health. This presentation can be used to introduce your institution to the benefits of open notes and how to adopt this practice with your patients. It guides you through the OpenNotes study, which sparked a movement towards more transparent notes across the nation.
White Paper - Infection Preventionists: Healthcare’s Guardians at the Gate Ne...Q-Centrix
This white paper examines a key player at the front lines of hospitals’ never-ending battles against HAIs –Infection Preventionists (IPs). It briefly explains their varied roles, responsibilities and new challenges, the difficulty in recruiting these highly sought-after experts, and why and how hospitals should be doing more to help overworked and understaffed IPs be successful. Lastly, it covers new technologies and IP support services that can be integrated into hospitals’ infection control practices.
Same-Visit Contraception: Implementation Strategies from the FieldJSI
According to the CDC and OPA, clients should have access to their contraceptive method of choice without unnecessary delays. Same-visit provision of contraception means providing immediate access to contraceptive methods using Quick Start. As long as a clinician can be reasonably certain a client is not pregnant, there is not medical reason to require clients to return for a follow-up visit or to initiate methods during menses. Clients face many barriers (work, child care, secure transportation) when asked to return for a second visit in order to initiate contraception and up to 50% of clients will not return for a follow up appointment.
Title X grantees and service sites across the country to identify successful strategies for implementing same-visit contraception including: 1. Stock devices and make supplies readily available, 2. Adjust systems for efficient and sustainable service delivery, 3. Engage, train, and support all staff.
To support implementation to Title X service sites, the FPNTC provides a Same-Visit Contraception Guide which includes: video case studies, slides and a discussion guide, interactive tools including checklists, calculators and printable sheets that can be posted at the office.
Kathy Talkington and Joe Swedberg - Antibiotic Stewardship – Recent Activitie...John Blue
Antibiotic Stewardship – Recent Activities in Human Medicine and Animal Agriculture - Kathy Talkington, Project Director, Antimicrobial Resistance, The Pew Charitable Trusts; Joe Swedberg, Chairman of the Board, Farm Foundation, from the 2018 NIAA Antibiotic Symposium: New Science & Technology Tools for Antibiotic Stewardship, November 13-15, 2018, Overland Park, KS, USA.
More presentations at https://www.youtube.com/playlist?list=PL8ZKJKD9cmEffjOrjbBvQZeN2_SZB_Skc
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
In pursuit of the 90–90–90 goals, emphasis has been placed on accelerating centralized laboratory HIV viral load testing of a population that is largely rural and decentralized. Successful
outcome requires effective specimen transport, laboratory testing, and results delivery. This paper focuses on the methods currently employed for results delivery. New innovations in this area are
yielding mixed results; we analyze different approaches and estimate the impact of each on achieving the third ‘90.’
With patient responsibility becoming an increasing part of clinics AR, you need to make sure you have an effective strategy in place. Learn how to maximize your collections without negatively impacting your relationships with your patients.
The Clinical Trials Portal supports improved cancer clinical trial activity data capture, monitoring and reporting across NSW. Find out more about cancer clinical trials in NSW.
Monitoring quality of care: making the most of dataNuffield Trust
Chris Sherlaw-Johnson, Senior Research Analyst at the Nuffield Trust, introduced the Monitoring quality of care conference and gives an overview of some of the approaches that we've been using at the Trust to identify where care quality has been improving, especially for frail and older people.
Patient Registries: A New Pillar of Modern CareQ-Centrix
www.q-centrix.com
A vital resource for patient data are registries. This white paper examines the rise of patient registries, how hospitals are taking advantage of the data, the challenges hospitals face in submitting quality information, and the benefits of real-time registry reporting.
AMCCBS Virtual2021 Conference Takeaways Part 2Carevive
Check out Debra Wujcik's takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms.
AIDSTAR-One Implementation of WHO's 2008 Pediatric HIV Treatment GuidelinesAIDSTAROne
In April 2008, the WHO Technical Reference Group for Pediatric HIV/ART and Care released a series of nine updated recommendations for diagnostic testing, initiation of treatment, and appropriate treatment regimens for HIV-exposed and infected infants. This technical brief outlines practical implementation considerations for program planners and policymakers working to incorporate these recommendations into their local efforts.
http://www.aidstar-one.com/implementation_whos_2008_pediatric_hiv_treatment_guidelines
OVC_HIVSTAT and Linkages to Care for Strengthened Collection, Analysis, and U...MEASURE Evaluation
This webinar focused on explaining the HIV Risk Assessment cascade and how it is related to OVC_HIVSTAT disaggregates. The presenters also provided guidance for how OVC_HIVSTAT data can be analyzed to enhance program outcomes.
HLT 362 V GCU Quiz 11. When a researcher uses a random samSusanaFurman449
HLT 362 V GCU
Quiz 1
1. When a researcher uses a random sample of 400 to make conclusions about a larger population, this is an example of:
· Descriptive statistics
· Demographics
· Inferential statistics
· Dependent variables
2. If a study is comparing number of falls by age, age is considered what type of variable?
· Interval
· Ordinal
· Ratio
· Nominal
3. Validity is:
· A data item, such as characteristics, numbers, properties, or quantities, that can be measured or counted.
· The extent to which an idea or measurement is well-founded and an accurate representation of the real world.
· A measurement level with equal distances between the points and a zero-starting point.
· Raw unorganized information from which conclusions can be made.
4. Data is defined as:
· A data item, such as characteristics, numbers, properties, or quantities, that can be measured or counted.
· The extent to which an idea or measurement is well-founded and an accurate representation of the real world.
· A measurement level with equal distances between the points and a zero-starting point.
· Raw unorganized information from which conclusions can be made.
5. The average of the collected data is known as:
· Mean
· Median
· Variance
· Range
6. The experimental or predictor variable is an example of:
· Extraneous variable
· Dependent variable
· Independent variable
· Nominal data
7. Level of measurement that defines the relationship between things and assigns an order or ranking to each thing is known as:
· Interval
· Ordinal
· Ratio
· Nominal
8. A variable is considered:
· A data item, such as characteristics, numbers, properties, or quantities, that can be measured or counted.
· A component of mathematics that looks at gathered data.
· Statistics designed to allow the researcher to infer characteristics regarding a population from sample population.
· External and internal influences within a study that can affect the validity and reliability of the outcomes.
9. External and internal influences within a study that can affect the validity and reliability of outcomes is called:
· Continuous variables
· Demographics
· Bias
· Standard deviation
10. The subset of the population to be studied is called:
· Sample
· Variable
· Population
· Demographic
Put the below in your own words into 1-2 paragraphs for the main conclusion and 1-2 paragraphs for the clinical application
Main conclusion:
The following is one example of a main conclusion and clinical applicability to assist you in formulating your take home message for the dissemination assignment. The details in these descriptions are intentionally detailed for your consideration. Do not include this level of detail in the dissemination assignment.
HPV study:
The Healthy People 2020 HPV vaccination goal of 80% of all United States adolescents[KG1] is not being met with current practices (citation). With insufficient vaccination, reduction in HPV-related disease ...
Representatives from the Philadelphia Department of Public Health (PDPH) presented an update on their strategic plan for sexual health at the February 2015 meeting of the Philadelphia Ryan White Part A Planning Council.
Hiv Prevention Nevada #ENDHIV #AIDSFREE#GOMOJO, INC.
Quality Management
The Nevada Ryan White Part B Program is committed to improving the quality of care and services for persons living with HIV and AIDS through continuous quality monitoring and improvement in a comprehensive performance measurement program.
NEVADA STATEWIDE HIV CONTINUUM OF CARE
The Nevada Statewide HIV Care Continuum and HIV Fast Facts shows all HIV/AIDS positive persons in the State of Nevada. This data includes persons who are engaged in care either in private clinics or a Ryan White Program, as well as, persons who are not engaged in care or not connected to a Ryan White Program.
Nevada Statewide HIV Continuum of Care 2017
Nevada Statewide HIV Continuum of Care 2016
2017 HIV Fast Facts
NEVADA RYAN WHITE PART B HIV CONTINUUM OF CARE
The Nevada Ryan White Part B Program HIV Care Cascade shows HIV/AIDS positive persons who have engaged in care and received at lease one service from the Nevada Ryan White Part B Program during the reported year.
HIV Care Cascade Calendar Year 2017
HIV Prevention Data Calendar Year 2017
NEVADA RYAN WHITE PART B QUALITY MANAGEMENT
The mission of the Nevada Ryan White Part B Program Quality Management Program is to improve access and ensure the highest quality medical care and supportive services through continuous evaluation, strategic planning and assessment, and the implementation of quality management and quality improvement projects.
Quality Management Plan 2018-2019
Quality Plan Performance Review 2018 Mid-Year Report
Calendar Year 2018 Reports
Viral Suppression by Disparities CY 2018- Age
Viral Suppression by Disparities CY 2018- Gender
Viral Suppression by Disparities CY 2018- HIV Risk Factor
Viral Suppression by Disparities CY 2018- Housing Status
Viral Suppression by Disparities CY 2018- Race and Ethnicity
Viral Suppression by Disparities CY 2018- All Disparity Data
Viral Suppression by Disparities CY 2018- ADAP Assistance
Grant Year 2018-2019 Mid-Year Reports
Viral Suppression by Disparities 2018 Mid-Year Report
Viral Suppression by Disparities 2018 Mid-Year Report-Age
Viral Suppression by Disparities 2018 Mid-Year Report-Gender
Viral Suppression by Disparities 2018 Mid-Year Report-HIV Risk Factor
Viral Suppression by Disparities 2018 Mid-Year Report-Housing
Viral Suppression by Disparities 2018 Mid-Year Report-Race and Ethnicity
Ryan White Part B Calendar Year 2017 Statistics
If you have any questions concerning Quality Management, please contact the person(s) below:
Samantha Penn, MBA
Management Analyst I
(Quality Assurance & Evaluation Analyst)
Phone: (702) 486-8103
Email: spenn@health.nv.gov
Core practices that are moving from a pilot state to implementation at scale: Many of the
barriers facing HIV programs are common across countries. PEPFAR’s ECTs (described below in
Sections 2.3.2 and 2.3.3) identified common issues affecting countries at various levels of
epidemic control and then developed a compendium of evidence-based solutions, approaches
and case-studies that highlight successful means of addressing common barriers. Additional
evidence-based approaches and case-studies will be incorporated into this living compendium
over time. As highlighted in this PEPFAR Solutions Platform, these practices can be rapidly
adapted and scaled to move countries forward.
Key considerations for all PEPFAR programs include:
• Bringing Interventions to Scale with Fidelity: Getting to HIV epidemic control is dependent on
several factors; not the least of which is the ability to rapidly scale successful interventions with
fidelity and demonstrated impact. However, the logistics of cost- effective programmatic scale
have proven challenging, with several implementation barriers. Implementation science
defines scalability as the capacity to expand or extend an intervention to account for a growth
factor that aims to fill a gap or address unmet need in a defined population group/geographic
area.
• Data and Information Technology: The enabling environment for data and information
technology is rapidly maturing across countries, creating space, opportunity, and needed
political will to harness the Data Revolution for epidemic control. OUs should consider
innovative ways to use data and information technology to improve efficiency and
sustainability in achieving epidemic control, beyond immediate PEPFAR indicator data
collection needs. As highlighted in the Data Revolution Innovation Toolkit, available on the
PEPFAR SharePoint, OUs are encouraged to explore, adapt, and scale these and other data
driven approaches to move country epidemic control forward.
Nevada profile 2015 stda re'port for cdc#GOMOJO, INC.
Core practices that are moving from a pilot state to implementation at scale: Many of the
barriers facing HIV programs are common across countries. PEPFAR’s ECTs (described below in
Sections 2.3.2 and 2.3.3) identified common issues affecting countries at various levels of
epidemic control and then developed a compendium of evidence-based solutions, approaches
and case-studies that highlight successful means of addressing common barriers. Additional
evidence-based approaches and case-studies will be incorporated into this living compendium
over time. As highlighted in this PEPFAR Solutions Platform, these practices can be rapidly
adapted and scaled to move countries forward.
Key considerations for all PEPFAR programs include:
• Bringing Interventions to Scale with Fidelity: Getting to HIV epidemic control is dependent on
several factors; not the least of which is the ability to rapidly scale successful interventions with
fidelity and demonstrated impact. However, the logistics of cost- effective programmatic scale
have proven challenging, with several implementation barriers. Implementation science
defines scalability as the capacity to expand or extend an intervention to account for a growth
factor that aims to fill a gap or address unmet need in a defined population group/geographic
area.
• Data and Information Technology: The enabling environment for data and information
technology is rapidly maturing across countries, creating space, opportunity, and needed
political will to harness the Data Revolution for epidemic control. OUs should consider
innovative ways to use data and information technology to improve efficiency and
sustainability in achieving epidemic control, beyond immediate PEPFAR indicator data
collection needs. As highlighted in the Data Revolution Innovation Toolkit, available on the
PEPFAR SharePoint, OUs are encouraged to explore, adapt, and scale these and other data
driven approaches to move country epidemic control forward.
Nevada state health division screen shot of site #GOMOJO, INC.
Nevada Prevention and Care Programs
Core practices that are moving from a pilot state to implementation at scale: Many of the
barriers facing HIV programs are common across countries. PEPFAR’s ECTs (described below in
Sections 2.3.2 and 2.3.3) identified common issues affecting countries at various levels of
epidemic control and then developed a compendium of evidence-based solutions, approaches
and case-studies that highlight successful means of addressing common barriers. Additional
evidence-based approaches and case-studies will be incorporated into this living compendium
over time. As highlighted in this PEPFAR Solutions Platform, these practices can be rapidly
adapted and scaled to move countries forward.
Key considerations for all PEPFAR programs include:
• Bringing Interventions to Scale with Fidelity: Getting to HIV epidemic control is dependent on
several factors; not the least of which is the ability to rapidly scale successful interventions with
fidelity and demonstrated impact. However, the logistics of cost- effective programmatic scale
have proven challenging, with several implementation barriers. Implementation science
defines scalability as the capacity to expand or extend an intervention to account for a growth
factor that aims to fill a gap or address unmet need in a defined population group/geographic
area.
• Data and Information Technology: The enabling environment for data and information
technology is rapidly maturing across countries, creating space, opportunity, and needed
political will to harness the Data Revolution for epidemic control. OUs should consider
innovative ways to use data and information technology to improve efficiency and
sustainability in achieving epidemic control, beyond immediate PEPFAR indicator data
collection needs. As highlighted in the Data Revolution Innovation Toolkit, available on the
PEPFAR SharePoint, OUs are encouraged to explore, adapt, and scale these and other data
driven approaches to move country epidemic control forward.
Core practices that are moving from a pilot state to implementation at scale: Many of the
barriers facing HIV programs are common across countries. PEPFAR’s ECTs (described below in
Sections 2.3.2 and 2.3.3) identified common issues affecting countries at various levels of
epidemic control and then developed a compendium of evidence-based solutions, approaches
and case-studies that highlight successful means of addressing common barriers. Additional
evidence-based approaches and case-studies will be incorporated into this living compendium
over time. As highlighted in this PEPFAR Solutions Platform, these practices can be rapidly
adapted and scaled to move countries forward.
Key considerations for all PEPFAR programs include:
• Bringing Interventions to Scale with Fidelity: Getting to HIV epidemic control is dependent on
several factors; not the least of which is the ability to rapidly scale successful interventions with
fidelity and demonstrated impact. However, the logistics of cost- effective programmatic scale
have proven challenging, with several implementation barriers. Implementation science
defines scalability as the capacity to expand or extend an intervention to account for a growth
factor that aims to fill a gap or address unmet need in a defined population group/geographic
area.
• Data and Information Technology: The enabling environment for data and information
technology is rapidly maturing across countries, creating space, opportunity, and needed
political will to harness the Data Revolution for epidemic control. OUs should consider
innovative ways to use data and information technology to improve efficiency and
sustainability in achieving epidemic control, beyond immediate PEPFAR indicator data
collection needs. As highlighted in the Data Revolution Innovation Toolkit, available on the
PEPFAR SharePoint, OUs are encouraged to explore, adapt, and scale these and other data
driven approaches to move country epidemic control forward.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
2016 indicator reference guide at-risk infants tested for hiv
1. 18
Prevention Services October 2015
Prevention of Mother-to-Child Transmission (PMTCT)/Pediatrics
Indicator code:
PMTCT_EID
1
Percentage of infants born to HIV-positive women who had a virologic HIV test done within
12 months of birth
Purpose: This indicator measures the extent to which infants born to HIV-positive women receive virologic testing to
determine their HIV status within the first 12 months of life. Early diagnosis of infants who acquired HIV during
pregnancy, delivery or in the early postpartum period is critical as infants have an increased risk of mortality if they go
undiagnosed and untreated.
NGI Mapping: C4.1 .D continuing slightly modified indicator, limited effect on trend analysis
PEPFAR Support
Target/Result Type:
Both Direct Service Delivery (DSD) and Technical Assistance-Service Delivery Improvement (TA-
SDI) targets and results should be reported to HQ
Numerator:
1
Number of infants who had a virologic HIV test within 12 months of birth during the
reporting period
Denominator:
1
Number of HIV-positive pregnant women identified in the reporting period (including
known HIV-positive women at entry into PMTCT)
Disaggregation(s):
1
Infants who received a virologic test within 2 months of birth
Infants who received their first virologic HIV test between 2 and 12 months of age
Infants with a positive virologic test result within 2 months of birth
Infants with a positive virologic test result within 2 and 12 months of birth
Data Source: Lab databases, patient records, service outlet log books, HIV-exposed infant registers or other
auditable source documentation at PEPFAR supported facilities.
Data Collection
Frequency:
Data should be collected continuously at the facility level and aggregated in time for PEPFAR
reporting cycles. Data should be reviewed regularly for the purposes of program management,
to monitor progress towards achieving targets, and to identify and correct any data quality
issues.
Method of Measurement:
A virologic test is a test used for HIV diagnosis in infants up to 18 months of age. The most commonly used form of
virologic testing is HIV DNA PCR on dried blood spots (DBS). Tests used for clinical monitoring of children on ART, such as
viral load quantification, should not be included here.
Infants tested should be counted once, even if they have had more than one virologic test done during the reporting
period.
Explanation of Numerator:
The numerator is calculated from PEPFAR-supported lab databases or program records. Only infants who have received a
virologic test by 12 months of birth should be counted and reported.
The numerator is calculated as follows:
The number of infants who received a virologic test within 12 months of birth
The numerator is disaggregated as follows:
The number of infants who received a test within 2 months of birth
The number of infants who received a virologic test for the first time between 2 and 12 months of age
The number of infants with a positive virologic test result within 12 months of birth
Explanation of Denominator:
Number of HIV-positive pregnant women identified during the reporting period (include known HIV-positive at entry).
This number serves as a proxy for the number of infants born to HIV-positive women. This denominator calculates a
coverage estimate of PEPFAR contribution to early infant diagnosis in PEPFAR-supported countries. If a national level
2. 19
coverage is desired, then the national estimate of HIV-positive pregnant women should be used as the denominator.
By using the number of the HIV-positive pregnant women identified in the reporting period as the denominator, this
indicator is harmonized and comparable with the PEPFAR PMTCT ARVs/ART indicator. This is a facility-based
denominator and not representative of the population.
Interpretation:
WHO recommends that national programs establish the capacity to conduct early virologic testing for HIV exposed
infants at 4-6 weeks, or as soon as possible thereafter, to guide clinical decision-making at the earliest possible stage.
Disaggregating this data by age provides a way for programs to track progress towards earlier testing of HIV-exposed
infants and therefore earlier identification of HIV-infected infants who should then be initiated on treatment as soon as
possible.
This indicator allows countries to monitor progress in reaching HIV-exposed infants with early infant testing as a critical
service that enables early identification of positive infants and reinforces the importance of exclusive breastfeeding and
maternal ARVs during the breastfeeding period for those with an initial negative result.
Since many countries do not have a unique patient identifier system for testing infants, and infants may receive more
than one virologic test according to national testing algorithms, countries may have difficulty distinguishing between an
initial virologic test and any subsequent virologic tests the infant receives (e.g., confirmatory virologic test in infant with
an initial positive virologic result, second virologic test in infant with an initial negative virologic result). As a result, the
data should be closely reviewed for double counting and efforts to deduplicate for reporting purposes should be made.
Double counting will overestimate the number of infants receiving a virologic test and in some instances, may more
accurately reflect the number of virologic tests conducted.
The indicator does not measure the quality of testing or the system in place for testing. A low value of the indicator
could, however, signal potential bottlenecks in the system, including poor management of HIV testing supply in country,
poor data collection, and sample transportation issues, etc.
PEPFAR Support:
DSD: Individuals will be counted as receiving direct service delivery support from PEPFAR when BOTH of the below
conditions are met: Provision of key staff or commodities AND frequent, at least quarterly, support to improve the
quality of services.
TA-SDI: Individuals will be counted as supported through TA-SDI when the point of service delivery receives support
from PEPFAR that meets the second criterion only: Frequent, at least quarterly support to improve the quality of
services.
1. PEPFAR is directly interacting with the patient or beneficiary in response to their health (physical, psychological,
etc.) care needs by providing key staff and/or essential commodities for routine service delivery. For infants
receiving PMTCT/HEI services, this includes procurement of critical commodities such as test kits, lab
commodities, or ARVs, or funding for salaries of HCW. Staff who are responsible for the completeness and
quality of routine patient records (paper or electronic) can be counted here; however, staff who exclusively fulfill
MOH and donor reporting requirements cannot be counted.
AND/OR
2. PEPFAR provides an established presence at and/or routinized, frequent (at least quarterly) support to those
services at the point of service delivery. For PMTCT/HEI services, this ongoing support for service delivery
improvement can include: training of PMTCT service providers, clinical mentoring and supportive supervision of
3. 20
PMTCT service sites, infrastructure/renovation of facilities, support of PMTCT service data collection, reporting,
data quality, QI/QA of PMTCT services support, ARV consumption forecasting and supply management, support
of lab clinical monitoring of patients, supporting patient follow-up/retention, support of mother mentoring
programs.
Additional References:
HIV-P15. The Global Fund to Fight AIDS, Tuberculosis and Malaria Monitoring and Evaluation Toolkit 4th
Edition.
November 2011. (http://www.theglobalfund.org/en/me/documents/toolkit/)
3.2. Global AIDS Progress Reporting 2013: Construction of Core indicators for monitoring the 2011 UN Political
Declaration on HIV/AIDS
(http://www.unaids.org/en/media/unaids/contentassets/documents/document/2013/GARPR_2013_guidelines_en.p
df)
Refer to the PMTCT/Peds Treatment TWG with further inquiries.